Clinical Trial Update: Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB [Phase 4]

View source ↗

Summary

Phase 4 trial assesses stopping tenofovir disoproxil fumarate after long-term virologic suppression in HBeAg-negative chronic hepatitis B and reports results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Viread (tenofovir disoproxil fumarate)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis B | Phase 4 | Status: COMPLETED | Results posted: 2017-08-29